Free Newsletters | Help  

  Current | By Company | NEW Products
Login ID:    Password:    Register for a FREE account
 NEWS

Industry News
Business
Organic
Food & Beverage
Sports Nutrition
Nutraceuticals
Regulatory
Research
Products
Practitioners
Retail
Events
People
On-line


 LISTINGS
  Categories
Products

Profiles
Publishers

 OPINION
  Editorials
Interviews
Up and Comers
Quality Initiatives

 
Blogs
Andrew Stewart  
Marc Ullman FYI Blog
Len Monheit Off The Cuff
James S. Tonkin - Formulating Beverages  
Jim Lassiter -- Good News/Bad News
The Nutrition Business Journal Blog

Join the NPIcenter LinkedIn Group Group
Join the Facebook page Page
Follow us on
Join the Facebook page


 FEATURES
 

Newsletter

  News Feeds
 
 SERVICES
  Log in
Register User
Add Company
Career Center
Advertise

 INFO CENTER
  Help
Contact Us
About NPI
Privacy Policy



 

Advertisement



Share Subscribe to NPIcenter Newsfeed

EPAX Confirms Its Oils Used in Latest Alzheimer's Study Conducted by Karolinska Institute
2007-06-26 - EPAX AS




AALESUND, Norway (June 26, 2007) — Omega-3 fatty acids were again proven to help serious symptoms coinciding with the memory decline characteristic for Alzheimer's disease, according to a recent study conducted by Yvonne Freund-Levi, M.D. from Sweden's Karolinska Institute. EPAX AS, a world-leading supplier of highly concentrated omega-3 EPA/DHA fatty acids, confirmed its EPAX 1050 TG oil was used in the study.

Recently published in the International Journal of Geriatric Psychiatry, Freund-Levi's study was a randomised, double-blind, placebo-controlled clinical trial. It showed that carriers of a specific gene common to those with Alzheimer's disease who received the omega-3 supplements responded positively to the omega-3s in regards to agitation symptoms. Those without the gene showed an improvement in symptoms of depression.

"These findings are surely encouraging to the millions of people affected by Alzheimer's disease. This study helps demonstrate the many positive impacts of omega-3 fatty acids, whether one has specific health concerns or is simply looking to stay healthy. We are pleased that EPAX could play a role in this impressive clinical trial," said Bjorn Refsum, CEO of EPAX AS.

A previous study, published in the Oct. 2006 issues of Archives of Neurology, conducted by Freund-Levi found that patients with early-stage Alzheimer's disease given EPAX 1050 TG omega-3 fatty acids showed significant improvement in memory decline compared to the control group.

EPAX 1050 TG is specially formulated for cognitive health. All of EPAX's oils are indication-specific and in addition to cognitive health, oils are available to address cardiovascular health, mood and mind health, joint health, pre-and post-natal health and weight management.

About EPAX AS
EPAX AS is headquartered in Aalesund with a global sales office in Lysaker/Oslo, Norway. Its production facility in Aalesund is GMP-approved by the Norwegian Medicines Agency for the manufacturing of API products. All of EPAX's business efforts reflect the company's core commitment: Purity | Quality | Innovation. These values represent EPAX's commitment to offering products that are safe, pure and of consistent quality. EPAX AS offers concentrated omega-3 EPA/DHA oils in the business-to-business segment under the brand name EPAX, available in a wide range of top-quality formulas with different EPA/DHA concentrations and ratios focused on specific health conditions. EPAX is available in TG or EE versions. For further information on EPAX AS, its products or clinical studies visit www.epax.com or contact marketing manager Gunilla Traberg at gunilla.traberg@epax.com.


# # #

 

Advertisement



Sponsored Links: Featured Links:
 

NPIcenter Address and Phone Number
Contact Us | Privacy Policy | Terms of Use | Advertise
New Hope Natural Media

 

SUPPLYEXPO Funtional Foods & Nutraceuticals Magazine Healthy Foods Conferences The Newport Summit - Executive Retreat Nutracon